-
The nocebo effect: should we be worried?
Luana Colloca
Editorial: Clinical Investigation
-
The nocebo effect: should we be worried?
Luana Colloca
Editorial: Clinical Investigation
-
The nocebo effect: should we be worried?
Luana Colloca
Editorial: Clinical Investigation
-
The nocebo effect: should we be worried?
Luana Colloca
Editorial: Clinical Investigation
-
The nocebo effect: should we be worried?
Luana Colloca
Editorial: Clinical Investigation
-
The nocebo effect: should we be worried?
Luana Colloca
Editorial: Clinical Investigation
-
The nocebo effect: should we be worried?
Luana Colloca
Editorial: Clinical Investigation
-
The nocebo effect: should we be worried?
Luana Colloca
Editorial: Clinical Investigation
-
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Henry Klassen
Editorial: Clinical Investigation
-
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Henry Klassen
Editorial: Clinical Investigation
-
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Henry Klassen
Editorial: Clinical Investigation
-
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Henry Klassen
Editorial: Clinical Investigation
-
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Henry Klassen
Editorial: Clinical Investigation
-
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Henry Klassen
Editorial: Clinical Investigation
-
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Henry Klassen
Editorial: Clinical Investigation
-
Stem cell clinical trials: toward cell-based therapy for retinal degenerations
Henry Klassen
Editorial: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ecallantide for the treatment of acute attacks of hereditary angioedema due to C1-inhibitor deficiency
Jonathan Bernstein, Joseph Biedenkapp
Review: Clinical Trail Outcomes: Clinical Investigation
-
New advances in the diagnosis and treatment of pediatric tuberculosis
Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomes: Clinical Investigation
-
New advances in the diagnosis and treatment of pediatric tuberculosis
Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomes: Clinical Investigation
-
New advances in the diagnosis and treatment of pediatric tuberculosis
Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomes: Clinical Investigation
-
New advances in the diagnosis and treatment of pediatric tuberculosis
Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomes: Clinical Investigation
-
New advances in the diagnosis and treatment of pediatric tuberculosis
Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomes: Clinical Investigation
-
New advances in the diagnosis and treatment of pediatric tuberculosis
Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomes: Clinical Investigation
-
New advances in the diagnosis and treatment of pediatric tuberculosis
Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomes: Clinical Investigation
-
New advances in the diagnosis and treatment of pediatric tuberculosis
Andrea T Cruz, Anna M Mandalakas
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
Review: Clinical Trail Outcomes: Clinical Investigation
-
Ranibizumab for the treatment of visual impairment due to diabetic macular edema: evidence from recent clinical trials
Laura Distefano, Anna Espax Boixadera, Charlotte Wolley-Dod, Vicente Martnez-Castillo, Jose Garcia-Arumi
Review: Clinical Trail Outcomes: Clinical Investigation
-
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Review Article: Clinical Investigation
-
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Review Article: Clinical Investigation
-
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Review Article: Clinical Investigation
-
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Review Article: Clinical Investigation
-
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Review Article: Clinical Investigation
-
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Review Article: Clinical Investigation
-
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Review Article: Clinical Investigation
-
Glucagon-like peptide-1 analogs in the treatment of Type 2 diabetes: a review of the Phase II and III trials
Marta Letizia Hribal, Giorgio Sesti
Review Article: Clinical Investigation